DGAP-Ad-hoc: Medios AG / Key word(s): Capital Increase/Forecast ​Medios AG plans capital increase in kind for the expansion of a business segment and announces annual forecast for 2018 12-March-2018 / 11:14 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Medios AG plans capital increase in kind for the expansion of a business segment and announces annual forecast for 2018 * Planned growth of the patient-specific preparations segment through the expansion of the manufacturing facilities for non-cytostatic products * Intended takeover of substantial operating units of BerlinApotheke Schneider & Oleski oHG * Significant increase in sales and earnings expected for 2018 financial year Berlin, 12 March 2018 - Medios AG ('Company') is planning to grow its patient-specific preparations segment through the expansion of the manufacturing facilities for non-cytostatic products. For this purpose, the company intends to take over substantial operating units of BerlinApotheke Schneider & Oleski oHG ('BerlinApotheke'). The acquisition will be carried out without the expenditure of cash by means of a capital increase in kind in exchange for new shares issued to the contributing party, Mr Manfred Schneider, CEO of Medios AG and co-owner of BerlinApotheke. A total of 900,000 new shares are to be issued in exchange for the contribution of the operating units. The value of the operating units that form the basis for this was confirmed to the Company by an auditor that it mandated and, in addition, must still be confirmed by a court-appointed auditor of contributions in kind. In the short term, the Management Board intends to conclude a contract for the contribution of the operating units and, with the approval of the Supervisory Board by using the existing authorised capital 2017/I, to increase the Company's share capital excluding shareholders' subscription rights by 900,000.00 euros from 13,664,019.00 euros to 14,564,019.00 euros through the issuance of 900,000 new bearer shares at an issue price of 1.00 euro each, and to allow Mr Schneider to subscribe to the new bearer shares. The new shares shall be introduced to trading on the regulated market of the Frankfurt Stock Exchange (General Standard). The required approval of the Supervisory Board and the relevant authorities is expected over the coming weeks. The Management Board of Medios AG expects the acquired operating units to begin production in June 2018 and, in consideration of these developments, forecasts Group sales of around 320 million euros (IFRS) and Group earnings before taxes (EBT*) totalling around 11 million euros (IFRS) for the 2018 financial year. This represents growth of 26 per cent and 37 per cent respectively compared to the preliminary figures already published for the 2017 financial year totalling 253.0 million euros (IFRS) and 8.0 million euros (IFRS) respectively. Planned EBT for the 2018 financial year do not include the non-cash special effect from the share option plan (SOP), which was introduced based on the decision made by the 2017 annual general meeting and which serves the participation and incentivisation of executives. According to preliminary calculations, the special effect results in extraordinary expenses of some 1.25 million euros and is therefore approximately at the same level of the non-cash special effect from the SOP in the 2017 financial year. Matthias Gärtner, CFO Medios AG * EBT is defined as net earnings before income taxes. Contact Medios AG, Friedrichstraße 113a, 10117 Berlin Phone: +49 30 232 5668 0; Fax: +49 30 232 5668 01 E-Mail: [email protected]; www.medios.ag --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: About Medios AG Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients. Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange. Disclaimer This release is a mandatory announcement pursuant to Art. 17 of the Market Abuse Regulation (MAR). The assessments contained therein are, as always, subject to the disclaimer provided below. Cautionary note regarding forward-looking statements/No duty to update This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification. Other This publication constitutes neither an offer to sell nor an invitation to buy securities. It may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction where such an announcement could be unlawful. This announcement does not constitute a recommendation concerning the purchase or sale of securities described in this announcement. --------------------------------------------------------------------------- 12-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Medios AG Friedrichstraße 113a 10117 Berlin Germany Phone: +49 30 232 566 - 800 Fax: 030 / 8321 8377 E-mail: [email protected] Internet: www.medios.ag ISIN: DE000A1MMCC8 WKN: A1MMCC Listed: Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf End of Announcement DGAP News Service --------------------------------------------------------------------------- 662575 12-March-2018 CET/CEST